Intelligene
↗Taipei, Taiwan
Intelligene Inc. is a clinical-stage biotechnology company headquartered in Taiwan, specializing in the development of innovative RNA-based therapeutics. The company leverages a proprietary platform that combines siRNA (small interfering RNA) technology with advanced delivery systems, including Lipid Nanoparticles (LNP) and exosomes, to target and degrade viral RNA within infected cells.
Founded in 2023, Intelligene focuses on addressing global health threats such as pandemics and seasonal influenza. The company has established a significant international presence with subsidiaries in Australia and the United States, and it is recognized for its 'decode and compile' approach to viral genome analysis, allowing for the rapid development of precise nucleic acid drugs against evolving pathogens.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:<$1M
Founded:2023
Ownership:public
Status:operating
FUNDING
Stage:Public (Post-IPO)
Total Raised:$15M+
Investors:GeneCompany (Australia), Baily Venture Capital, Medical Research Future Fund (Australia)
STOCK
Exchange:TPEX
Ticker:7832
Market Cap:$300M
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1 (Scheduled 2025)
Modalities:siRNA, RNAi, LNP, Exosomes
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Intelligene LLC (USA), Intelligene Pty Ltd (Australia)
Key Partnerships:Kirby Institute (Australia) - BRIDGE Program partner, BARDA - Rapid Response Partnership Vehicle (RRPV) member
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Vir Biotechnology, Intellia Therapeutics
LEADERSHIP
Key Executives:
Jerry Huang (Hsien-Jung Huang) - Chairman & CEO
Patty Sung (Pei-Yi Sung) - President & COO
Scientific Founders:Jerry Huang
Board Members:Jerry Huang, Lin Yu-Hsin (Chairman of Lin BioScience)
LINKS
Website:intelli-gene.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Intelligene. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.